-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DM2p13eY2uUWGCJz98nLJQ0NvNS8RM5KTPCH06vPiX4sennWP4yRw+3dDahdnWdw A5QW4ynQlQDhx7m1MJCEOA== 0000912057-02-021904.txt : 20020524 0000912057-02-021904.hdr.sgml : 20020524 20020524141414 ACCESSION NUMBER: 0000912057-02-021904 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020523 ITEM INFORMATION: Other events FILED AS OF DATE: 20020524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 02662057 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 8-K 1 a2080995z8-k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 -------------- Date of Report (Date of earliest event reported): May 23, 2002 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) MASSACHUSETTS 000-19319 04-3039129 (state or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.)
130 WAVERLY STREET CAMBRIDGE, MA 02139 --------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 444-6100 - -------------------------------------------------------------------------------- ITEM 5. OTHER EVENTS. On May 23, 2002, Lynne H. Brum, the Company's Vice President of Corporate Development and Communications, entered into a plan with Goldman, Sachs & Co., pursuant to which Goldman will undertake to sell, subject to a limit order, an aggregate of 23,816 shares of the Company's stock issuable upon exercise of options held by Ms. Brum. Sales under the plan are to begin no earlier than 90 days after adoption of the plan, and will take place at specified intervals between August 29, 2002 and August 14, 2003. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: May 24, 2002 /s/ IAN F. SMITH ------------------------------------------ Vice President and Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----